[HTML][HTML] DNA hypermethylation-induced miR-182 silence targets BCL2 and HOXA9 to facilitate the self-renewal of leukemia stem cell, accelerate acute myeloid …
S Ye, F Xiong, X He, Y Yuan, D Li, D Ye, L Shi, Z Lin… - Theranostics, 2023 - ncbi.nlm.nih.gov
Rationale: microRNAs (miRNAs) are frequently deregulated and play important roles in the
pathogenesis and progression of acute myeloid leukemia (AML). miR-182 functions as an …
pathogenesis and progression of acute myeloid leukemia (AML). miR-182 functions as an …
Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia
Less-intensive induction therapies are increasingly used in older patients with acute myeloid
leukemia (AML). Using an AML composite model (AML-CM) assigning higher scores to …
leukemia (AML). Using an AML composite model (AML-CM) assigning higher scores to …
Outcome of patients with newly diagnosed AML admitted to the ICU, including preemptive admission–a multi-center study
C Desprez, A Kouatchet, T Marchand, JB Mear… - Annals of …, 2023 - Springer
Acute myeloid leukemia (AML) can lead to life-threatening complications that may require
intensive care unit (ICU) management. It has been advocated that early preemptive (ePE) …
intensive care unit (ICU) management. It has been advocated that early preemptive (ePE) …
Novel biomarkers to identify complicated course of febrile neutropenia in hematological patients receiving intensive chemotherapy
E Jantunen, S Hämäläinen, K Pulkki… - European Journal of …, 2024 - Wiley Online Library
Febrile neutropenia (FN) is a common consequence of intensive chemotherapy in
hematological patients. More than 90% of the patients with acute myeloid leukemia (AML) …
hematological patients. More than 90% of the patients with acute myeloid leukemia (AML) …
WT1 facilitates the self-renewal of leukemia-initiating cells through the upregulation of BCL2L2: WT1-BCL2L2 axis as a new acute myeloid leukemia therapy target
B Zhou, X Jin, W Jin, X Huang, Y Wu, H Li… - Journal of translational …, 2020 - Springer
Abstract Background Overexpression of Wilms' tumor-1 (WT1) transcription factor facilitates
proliferation in acute myeloid leukemia (AML). However, whether WT1 is enriched in the …
proliferation in acute myeloid leukemia (AML). However, whether WT1 is enriched in the …
Simple acute phase protein score to predict long‐term survival in patients with acute myeloid leukemia
High levels of acute phase reactants can be associated with adverse outcome in patients
with various solid tumor types. For patients with acute myeloid leukemia (AML), this …
with various solid tumor types. For patients with acute myeloid leukemia (AML), this …
Lactate level is an independent predictor of mortality in patients with hematologic malignancy receiving urgent chemotherapy in intensive care unit
SMK Bozgul, IA Kurtulmus, A Gunes, G Koymen… - Current Research in …, 2024 - Elsevier
Background Intensive care unit (ICU) survival of cancer patients has improved. Urgent
chemotherapy has become feasible in critically ill patients with specific organ dysfunction …
chemotherapy has become feasible in critically ill patients with specific organ dysfunction …
Febrile neutropenia in patients with acute myeloid leukemia: Outcome in relation to qSOFA score, C‐reactive protein, and blood culture findings
M Lappalainen, S Hämäläinen… - European Journal of …, 2020 - Wiley Online Library
Abstract Objectives To evaluate quick Sequential Organ Failure Assessment (qSOFA) score
during febrile neutropenia (FN) in adult patients receiving intensive chemotherapy for acute …
during febrile neutropenia (FN) in adult patients receiving intensive chemotherapy for acute …
[PDF][PDF] Assessment of febrile neutropenia in hematological patients
M Lappalainen - 2021 - dspace.uef.fi
Febrile neutropenia after intensive treatment of hematological malignancies predisposes the
patient to serious infections. Febrile neutropenia periods are usually not associated with …
patient to serious infections. Febrile neutropenia periods are usually not associated with …
Multi-center 11-year experience of intensive versus less-intensive induction therapy for high-risk and vulnerable patients with newly-diagnosed acute myeloid …
Less-intensive induction therapies are increasingly used in older patients with acute myeloid
leukemia, assuming they are better than intensive induction. Using an AML-composite …
leukemia, assuming they are better than intensive induction. Using an AML-composite …